World

French film icon and animal rights activist Brigitte Bardot dies at 91

Dec 29, 2025

Paris [France], December 29: French film legend Brigitte Bardot has died at the age of 91 at her home in southern France, her foundation said on Sunday, as tributes poured in from politicians and stars alike.
The Brigitte Bardot Foundation said in a statement, "The Brigitte Bardot Foundation announces with immense sadness the passing of its founder and president, Madame Brigitte Bardot, a world-renowned actress and singer, who chose to abandon her prestigious career to dedicate her life and energy to animal welfare and her foundation," PA news agency reported.
The statement added: "The Brigitte Bardot Foundation wishes to pay tribute to the memory of an exceptional woman who gave up everything for a world more respectful of animals.
"Her legacy remains, living through the actions and battles that the foundation pursues with the same passion and the same loyalty to her ideals."
Bardot was known worldwide as one of the most famous women in post-war cinema. Known widely as BB because of her initials, pronounced bebe, the French word for baby, Bardot starred in dozens of movies, with Et Dieu Crea La Femme (And God Created Woman) often seen as the film that propelled her to worldwide fame.
Source: Qatar Tribune

More news

Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial

Tampa (Florida) [US], November 2: Sirolimus-coated balloon (SCB) strategy was non-inferior to contemporary everolimus-eluting stents (EES) for Target Lesion Failure (TLF) at 12 months in patients with de novo coronary artery disease. These are the results of the TRANSFORM II randomised trial, presented today as a Late-Breaking Clinical Trial at TCT 2026 and accepted in The Lancet which confirm how MagicTouch Sirolimus Coated Balloon (Concept Medical) matches contemporary best in class stent. Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease.

Nov 02, 2026